Lucentis 10 mg/ml solution for injection, Ranibizumab
CR213-20
Phase 3 small_molecule active
Quick answer
Lucentis 10 mg/ml solution for injection, Ranibizumab for wet macula degeneration is a Phase 3 program (small_molecule) at CuraTeQ Biologics s.r.o with 1 ClinicalTrials.gov record(s).
Program details
- Company
- CuraTeQ Biologics s.r.o
- Indication
- wet macula degeneration
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active